Pharmacyte Biotech Inc (PMCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 01-2025 | 10-2024 | 07-2024 | 04-2024 | 01-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 18,907 | 21,952 | 23,421 | 334 | -1,013 |
| Accounts payable and accrued liabilities | 96 | -41 | 165 | 261 | 356 |
| Other Working Capital | 99 | -324 | 368 | 299 | 212 |
| Other Operating Activity | -21,039 | -23,015 | -24,328 | -3,045 | -1,373 |
| Operating Cash Flow | $-1,938 | $-1,428 | $-373 | $-2,152 | $-1,819 |
| Cash Flows From Investing Activities | |||||
| Other Investing Activity | -7,000 | -7,000 | -7,000 | -5,000 | -5,000 |
| Investing Cash Flow | $-7,000 | $-7,000 | $-7,000 | $-5,000 | $-5,000 |
| Cash Flows From Financing Activities | |||||
| Common Stock Repurchased | -2,371 | -2,146 | -742 | -28,198 | -27,023 |
| Other Financing Activity | -22,487 | -18,766 | -9,430 | 17,490 | 27,012 |
| Financing Cash Flow | $-24,858 | $-20,912 | $-10,172 | $-10,708 | $-11 |
| Exchange Rate Effect | -1 | 0 | 0 | -1 | 0 |
| Beginning Cash Position | 50,180 | 50,180 | 50,180 | 68,040 | 68,040 |
| End Cash Position | 16,384 | 20,840 | 32,635 | 50,180 | 61,210 |
| Net Cash Flow | $-33,797 | $-29,340 | $-17,545 | $-17,860 | $-6,830 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,938 | -1,428 | -373 | -2,152 | -1,819 |
| Free Cash Flow | -1,938 | -1,428 | -373 | -2,152 | -1,819 |